We propose that while the direct killing of TREG, mediated by anti-CTLA-4 antibodies, is the primary mechanism through which they exert their anti-tumour effects, selective blockade of sCTLA-4 contributes to ‘releasing the brakes’ of the antigen-specific immune response (Figures 1 and 2). Here, CTLA4 is linked to neoplasm.